LUGANO, October 4th, 2018 • Psoriasis is a chronic disease affecting 2-4% of the world’s population. A new anti-psoriasis spray now in phase III trial offers more comfort to patients, and improves dose control. The first patient has now entered the trial. Lipidor’s Calcipotriol Spray is being evaluated over 8 weeks of treatment in a randomized…
LUGANO, October 2nd, 2018 • The Institute for Research in Biomedicine (IRB-USI, Bellinzona, www.irb.ch), active in human immunology research, and Cerbios-Pharma SA (Barbengo, Lugano), a company active in developing and producing active pharmaceutical ingredients (API), have started collaborating to develop Antibodies’ derivatives to treat Acute Myeloid Leukemia (AML), which makes it possible to target leukemia cells…
Lugano/Bern, September 7, 2018 • On September 7, Cerbios was honored by the visit of the US Ambassador to Switzerland and Liechtenstein, Edward McMullen Jr. Aim of the visit of the Ambassador was to meet Cerbios’ top management and shareholder in order to have a better view and understanding of Cerbios’ ongoing and future activities in the…
LUGANO, April 19th, 2018 • Cerbios-Pharma SA (from now on “Cerbios”) is pleased to announce the publication of a comprehensive review on its proprietary Probiotic Active Ingredient E. faecium SF68® (SF68®). In an article, published in the Scientific Journal “Beneficial Microbes”, extensive information is provided on the efficacy and safety of SF68® supported by well established scientific and surveillance…
LUGANO, April 17th, 2018 • It is with pleasure that we announce that on Friday the 27th of April 2018, Cerbios-Pharma SA (from now on CERBIOS) successfully passed a general FDA GMP inspection. Originally, the inspection was scheduled to last five days. Due to the excellent results, the inspector decided to close the audit in the middle of…
LUGANO, June 1st, 2017 • Cerbios-Pharma SA is pleased to announce that Mr. Denis Angioletti has joined our team as Chief Commercial Officer and Francesca Nembri is our new Qualified Person and QA/DRA Director. Andrea Tam (former CCO) has been promoted to CEO of a Cerbios’ sister company and Clarissa Gobetti (former QP) has also…
Stockholm/Lugano, April 25th, 2017 • It is a pleasure to share the latest diffusion study results on the AKVANO® drug delivery system developed and owned by our partner Lipidor AB (from now on LIPIDOR). Results from the new in vitro permeation experiments, which have been performed on ketoprofen, diclofenac diethylamine and diclofenac sodium formulations in…
LUGANO, January 1st, 2017 • Following a corporate restructuring and the streamlining of operations at Cerbios-Pharma SA (from now on CERBIOS), we are proud to announce the promotion of Claudio Pozzoli to the position of Chief Scientific Officer (CSO). Claudio Pozzoli will lead the newly created R&D Division, which includes both divisions: Chemical and Biological.…
